50 citations
,
December 2006 in “Bone” This study found that the steroidal aromatase inhibitor exemestane stimulated proliferation of human osteoblast cells, suggesting both androgen receptor-dependent and independent pathways are involved.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” This review discusses the efficacy and safety of exemestane as a treatment for estrogen-receptor-positive breast cancer and reports no new clinical results.
4 citations
,
March 2023 in “IP International Journal of Comprehensive and Advanced Pharmacology” This study explored the development of a self nanoemulsifying drug delivery system to enhance the solubility and oral bioavailability of exemestane HCl for breast cancer therapy.
January 2007 in “Zhōnghuá yàoxué zázhì” This study concluded that two exemestane preparations are bioequivalent, using a high-performance liquid chromatographic mass spectrometric method to measure concentrations in human plasma.
2 citations
,
May 2025 in “Frontiers in Pharmacology” In this study, analysis of FDA data revealed a substantial risk of dermatologic adverse events with aromatase inhibitors, especially anastrozole and exemestane, highlighting the importance of dermatologic monitoring during such therapies.